$BIOCQ
Biocept Inc

2016 Q4 Form 10-K Financial Statement

#000156459017005382 Filed on March 28, 2017

View on sec.gov

Income Statement

Concept 2016 Q4 2016 2015 Q4
Revenue $1.292M $3.223M $218.3K
YoY Change 491.7% 428.46% 188.65%
Cost Of Revenue $1.899M $6.920M $1.276M
YoY Change 48.9% 50.56% 107.53%
Gross Profit -$607.9K -$3.697M -$1.057M
YoY Change -42.51% -7.26% 96.16%
Gross Profit Margin -47.06% -114.7% -484.42%
Selling, General & Admin $2.816M $11.61M $2.669M
YoY Change 5.53% 21.41% 25.77%
% of Gross Profit
Research & Development $668.4K $2.713M $784.4K
YoY Change -14.79% -5.05% -26.71%
% of Gross Profit
Depreciation & Amortization $70.00K $322.0K $70.00K
YoY Change 0.0% 23.37% 0.0%
% of Gross Profit
Operating Expenses $3.485M $14.33M $3.453M
YoY Change 0.91% 15.32% 8.17%
Operating Profit -$4.092M -$18.03M -$4.510M
YoY Change -9.27% 9.84% 20.88%
Interest Expense -$130.0K $525.9K -$150.0K
YoY Change -13.33% -17.89% 0.0%
% of Operating Profit
Other Income/Expense, Net $40.00K -$372.2K $40.00K
YoY Change 0.0% -30.7%
Pretax Income -$4.190M -$18.40M -$4.620M
YoY Change -9.31% 8.55% 19.07%
Income Tax $0.00 $2.053K $0.00
% Of Pretax Income
Net Earnings -$4.187M -$18.40M -$4.618M
YoY Change -9.33% 8.55% 18.96%
Net Earnings / Revenue -324.17% -570.86% -2115.37%
Basic Earnings Per Share -$0.27 -$1.92 -$0.73
Diluted Earnings Per Share -$0.27 -$1.92 -$0.73
COMMON SHARES
Basic Shares Outstanding 15.62M 9.578M 6.307M
Diluted Shares Outstanding 15.62M 9.578M 6.307M

Balance Sheet

Concept 2016 Q4 2016 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.610M $4.610M $8.820M
YoY Change -47.73% -47.73% 64.55%
Cash & Equivalents $8.820M
Short-Term Investments
Other Short-Term Assets $480.0K $480.0K $440.0K
YoY Change 9.09% 9.09% 29.41%
Inventory $549.0K $550.0K $350.0K
Prepaid Expenses
Receivables $129.0K $130.0K $30.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $5.772M $5.770M $9.640M
YoY Change -40.12% -40.15% 63.32%
LONG-TERM ASSETS
Property, Plant & Equipment $1.806M $1.810M $950.0K
YoY Change 90.14% 90.53% 43.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.808M $1.810M $946.9K
YoY Change 90.94% 90.53% 42.95%
TOTAL ASSETS
Total Short-Term Assets $5.772M $5.770M $9.640M
Total Long-Term Assets $1.808M $1.810M $946.9K
Total Assets $7.580M $7.580M $10.59M
YoY Change -28.4% -28.42% 61.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $960.0K $960.0K $632.5K
YoY Change 51.77% 52.38% -1.38%
Accrued Expenses $1.160M $1.160M $966.9K
YoY Change 19.97% 19.59% 38.15%
Deferred Revenue
YoY Change
Short-Term Debt $80.00K $80.00K $40.00K
YoY Change 100.0% 100.0% 33.33%
Long-Term Debt Due $2.200M $2.200M $1.700M
YoY Change 29.41% 29.41% 2733.33%
Total Short-Term Liabilities $4.394M $4.390M $3.341M
YoY Change 31.51% 31.44% 133.49%
LONG-TERM LIABILITIES
Long-Term Debt $1.900M $1.900M $2.930M
YoY Change -35.15% -35.15% -38.96%
Other Long-Term Liabilities $620.0K $620.0K $620.0K
YoY Change 0.0% 0.0% 12.73%
Total Long-Term Liabilities $2.526M $2.520M $3.553M
YoY Change -28.91% -29.01% -33.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.394M $4.390M $3.341M
Total Long-Term Liabilities $2.526M $2.520M $3.553M
Total Liabilities $6.920M $6.920M $6.894M
YoY Change 0.37% 0.44% 1.6%
SHAREHOLDERS EQUITY
Retained Earnings -$173.6M -$155.2M
YoY Change 11.85% 12.26%
Common Stock $174.3M $158.9M
YoY Change 9.67% 15.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $658.7K $660.0K $3.693M
YoY Change
Total Liabilities & Shareholders Equity $7.578M $7.580M $10.59M
YoY Change -28.42% -28.42% 61.26%

Cashflow Statement

Concept 2016 Q4 2016 2015 Q4
OPERATING ACTIVITIES
Net Income -$4.187M -$18.40M -$4.618M
YoY Change -9.33% 8.55% 18.96%
Depreciation, Depletion And Amortization $70.00K $322.0K $70.00K
YoY Change 0.0% 23.37% 0.0%
Cash From Operating Activities -$4.440M -$15.70M -$4.250M
YoY Change 4.47% 3.63% 33.23%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K $482.1K -$50.00K
YoY Change 80.0% 191.88% -73.68%
Acquisitions
YoY Change
Other Investing Activities $30.00K $30.00K
YoY Change
Cash From Investing Activities -$60.00K -$450.0K -$50.00K
YoY Change 20.0% 164.71% -73.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.430M 11.94M 590.0K
YoY Change 1328.81% -36.42% -942.86%
NET CHANGE
Cash From Operating Activities -4.440M -15.70M -4.250M
Cash From Investing Activities -60.00K -450.0K -50.00K
Cash From Financing Activities 8.430M 11.94M 590.0K
Net Change In Cash 3.930M -4.210M -3.710M
YoY Change -205.93% -221.68% 7.54%
FREE CASH FLOW
Cash From Operating Activities -$4.440M -$15.70M -$4.250M
Capital Expenditures -$90.00K $482.1K -$50.00K
Free Cash Flow -$4.350M -$16.18M -$4.200M
YoY Change 3.57% 5.66% 40.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1588058
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3340788
CY2015Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
291189
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-16410803
CY2016 us-gaap Other Income
OtherIncome
153648
CY2016 dei Trading Symbol
TradingSymbol
BIOC
CY2016 dei Entity Registrant Name
EntityRegistrantName
BIOCEPT INC
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001044378
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q4 us-gaap Cash
Cash
8821329
CY2016Q4 us-gaap Cash
Cash
4609332
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
128969
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016Q2 dei Entity Public Float
EntityPublicFloat
14573995
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22280247
CY2015 us-gaap Interest Paid Net
InterestPaidNet
405715
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
482065
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
1750
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
174292781
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173635870
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
658661
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7578326
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4393552
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
778643
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2857770
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5686398
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5054230
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17499397
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17499397
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.07
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-220569
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.07
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
322029
CY2016 bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
31659
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1593947
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
100005
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
94769
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
168115
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-494734
CY2016 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
55444
CY2016 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-36965
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15697058
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-451403
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2713367
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6560425
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-18025037
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158928627
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155236548
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
3692735
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10586918
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2016 us-gaap Revenues
Revenues
3223096
CY2016 us-gaap Cost Of Revenue
CostOfRevenue
6920111
CY2015 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3880386
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
17020712
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
21248133
CY2015 us-gaap Other Income
OtherIncome
102432
CY2016Q4 us-gaap Inventory Net
InventoryNet
549045
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
484649
CY2016Q4 us-gaap Assets Current
AssetsCurrent
5771995
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1806331
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
262674
CY2016Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1934665
CY2015Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
2638487
CY2016Q4 bioc Interest Payable Noncurrent
InterestPayableNoncurrent
227177
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
397292
CY2016Q4 us-gaap Liabilities
Liabilities
6919665
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
656
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-372232
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18397269
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2053
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-18399322
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9578285
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9578285
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.92
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.92
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1377824
CY2015 bioc Stock Issued During Period Value Pursuant To Stock Purchase Agreement Net Of Issuance Costs
StockIssuedDuringPeriodValuePursuantToStockPurchaseAgreementNetOfIssuanceCosts
958000
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.68
CY2016 bioc Class Of Warrant Or Right Expiry Period
ClassOfWarrantOrRightExpiryPeriod
P5Y
CY2016 bioc Underwriter Common Stock Grants Period
UnderwriterCommonStockGrantsPeriod
P45D
CY2016 bioc Common Shares Issuable To Underwriters Under Granted Option
CommonSharesIssuableToUnderwritersUnderGrantedOption
400000
CY2016Q4 bioc Shares Issued To Underwriters Under Over Allotment Options Per Share
SharesIssuedToUnderwritersUnderOverAllotmentOptionsPerShare
3.75
CY2014Q4 bioc Offering Costs Recorded In Prepaid Expenses And Other Current Assets Reclassified To Common Stock Issuance Costs
OfferingCostsRecordedInPrepaidExpensesAndOtherCurrentAssetsReclassifiedToCommonStockIssuanceCosts
63111
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6556685
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6556685
CY2015 us-gaap Revenues
Revenues
609909
CY2015 us-gaap Cost Of Revenue
CostOfRevenue
4596158
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-537115
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16947918
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1608
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-16949526
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5512989
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5512989
CY2016Q1 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
1062500
CY2016Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
812500
CY2016Q4 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
1000000
CY2015 bioc Shares Issued Upon Exercise Of Common Stock Warrants Value
SharesIssuedUponExerciseOfCommonStockWarrantsValue
9760060
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1593947
CY2016 bioc Stock Issued During Period Value Pursuant To Stock Purchase Agreement Net Of Issuance Costs
StockIssuedDuringPeriodValuePursuantToStockPurchaseAgreementNetOfIssuanceCosts
465293
CY2016Q2 bioc Class Of Warrant Or Right Expiry Period
ClassOfWarrantOrRightExpiryPeriod
P5Y
CY2016Q2 bioc Warrants Issued Grant Date Fair Value
WarrantsIssuedGrantDateFairValue
2000000
CY2016Q2 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
653000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
261409
CY2015 bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
34437
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1377824
CY2015 us-gaap Paid In Kind Interest
PaidInKindInterest
119732
CY2016 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
30662
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
23600
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
126106
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
80432
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-51790
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
332732
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
240901
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
165543
CY2015 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
110021
CY2015 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
1163
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15154841
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
30662
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
165160
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-165160
CY2015 bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
9788057
CY2016 bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
13771301
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9760060
CY2015 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
74697
CY2016 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
86227
CY2015 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
71232
CY2016 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
510123
CY2015 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
625440
CY2016 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1238487
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
18776748
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
11936464
CY2015 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
3456747
CY2016 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-4211997
CY2014Q4 us-gaap Cash
Cash
5364582
CY2016 us-gaap Interest Paid Net
InterestPaidNet
358632
CY2015 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2184
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2053
CY2016 bioc Warrants Issued Grant Date Fair Value
WarrantsIssuedGrantDateFairValue
7700000
CY2016 bioc Overallotment Option Issued To Underwriters Under Warrants Granted
OverallotmentOptionIssuedToUnderwritersUnderWarrantsGranted
400000
CY2016 bioc Shares Issued To Underwriters Under Over Allotment Options Grant Date Fair Value
SharesIssuedToUnderwritersUnderOverAllotmentOptionsGrantDateFairValue
1600000
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.90
CY2016Q4 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
0.57
CY2016Q4 bioc Underwriter Common Stock Grants Period
UnderwriterCommonStockGrantsPeriod
P30D
CY2016Q4 bioc Shares Issued To Underwriters Under Over Allotment Options Per Share
SharesIssuedToUnderwritersUnderOverAllotmentOptionsPerShare
1.0331
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0009
CY2016Q4 bioc Shares Issued To Underwriters Under Over Allotment Options Grant Date Fair Value
SharesIssuedToUnderwritersUnderOverAllotmentOptionsGrantDateFairValue
800000
CY2015 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
337085
CY2016 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
975406
CY2016 bioc Aggregate Net Book Value Of Fixed Assets
AggregateNetBookValueOfFixedAssets
270377
CY2016 bioc Equipment Financings With Remaining Outstanding Balances
EquipmentFinancingsWithRemainingOutstandingBalances
239994
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
19546
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
64300
CY2014 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
58066
CY2015 bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
79896
CY2016 bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
547378
CY2016 us-gaap Financial Guarantee Insurance Contracts Premium Receivable Proceeds From Premiums Received
FinancialGuaranteeInsuranceContractsPremiumReceivableProceedsFromPremiumsReceived
3933
CY2016Q2 bioc Issuance Of Warrants To Purchase Common Stock Shares
IssuanceOfWarrantsToPurchaseCommonStockShares
1163526
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company and Business Activities </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample. The Company&#8217;s assays provide, and its planned future assays will provide, information to oncologists and other physicians that enable them to select appropriate personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers and markers of their disease and when traditional methodologies such as tissue biopsies are insufficient or unavailable. The Company&#8217;s assays have potential to provide more contemporaneous information on the characteristics of a patients&#8217; disease compared with traditional methodologies such as tissue biopsy and imaging.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company&#8217;s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July&#160;23, 2013. </p></div>
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates these estimates and judgments, including those related to inventories, long-lived assets, income taxes, and stock-based compensation. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p></div>
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third party payors of the Company&#8217;s services such as Medicare and individual insurance companies and other third party payors. The Company&#8217;s client base consists of a large number of geographically dispersed clients diversified across various customer types. Approximately 41% and 40% of the Company&#8217;s total revenues during the years ended December 31, 2015 and 2016, respectively, were associated with Medicare reimbursement. For the year ended December&#160;31, 2015, the first, second, and third most significant third party payors not associated with Medicare reimbursement accounted for approximately 21%, 7%, and 6%, respectively, of total revenues. For the year ended December&#160;31, 2016, the first, second, and third most significant third party payors not associated with Medicare reimbursement accounted for approximately 19%, 11%, and 9%, respectively, of total revenues. For the year ended December&#160;31, 2015, the first, second, and third most significant individual clients or practices accounted for approximately 12%, 9%, and 5%, respectively, of total revenues. For the year ended December&#160;31, 2016, the first, second, and third most significant individual clients or practices accounted for approximately 10%, 7%, and 4%, respectively, of total revenues. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one reportable business segment and historically has derived most revenues only from the United States.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain components used in the Company&#8217;s current or planned products are currently sourced from one supplier for which alternative suppliers exist, but the Company has not validated the product(s) of such alternative supplier(s), and substitutes for these components may not be obtained easily or may require substantial design or manufacturing modifications. </p></div>
CY2016 bioc Unconditional Purchase Commitment Frequency Of Periodic Payment
UnconditionalPurchaseCommitmentFrequencyOfPeriodicPayment
Quarterly
CY2016 us-gaap Unrecorded Unconditional Purchase Obligation Date
UnrecordedUnconditionalPurchaseObligationDate
2020-05-31
CY2016Q4 bioc Other Non Interest Bearing Current Liabilities
OtherNonInterestBearingCurrentLiabilities
2100000
CY2015Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9800000
CY2015Q1 bioc Proceeds From Gross Warrant Exercises Outstanding
ProceedsFromGrossWarrantExercisesOutstanding
2700000
CY2015Q1 bioc Warrants Exercisable Exercise Price Per Share
WarrantsExercisableExercisePricePerShare
4.68
CY2015Q1 bioc Warrants Exercisable Exercise Price Per Share Expiration Period
WarrantsExercisableExercisePricePerShareExpirationPeriod
2020-02
CY2016Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.33
CY2016 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. The one-for-three reverse stock split was effected on September 29, 2016.
CY2015 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2016 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
one supplier
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2015 us-gaap Depreciation
Depreciation
261000
CY2016 us-gaap Depreciation
Depreciation
322000
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2016 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
42000
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
79000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1400000
CY2015Q1 bioc Warrants Issued Grant Date Fair Value
WarrantsIssuedGrantDateFairValue
7700000
CY2015Q1 bioc Underwriter Common Stock Grants Period
UnderwriterCommonStockGrantsPeriod
P45D
CY2015Q1 bioc Common Shares Issuable To Underwriters Under Granted Option
CommonSharesIssuableToUnderwritersUnderGrantedOption
400000
CY2015Q1 bioc Shares Issued To Underwriters Under Over Allotment Options Per Share
SharesIssuedToUnderwritersUnderOverAllotmentOptionsPerShare
3.75
CY2015Q1 bioc Overallotment Option Issued To Underwriters Under Warrants Granted
OverallotmentOptionIssuedToUnderwritersUnderWarrantsGranted
400000
CY2015Q1 bioc Shares Issued To Underwriters Under Over Allotment Options Grant Date Fair Value
SharesIssuedToUnderwritersUnderOverAllotmentOptionsGrantDateFairValue
1600000
CY2016Q4 us-gaap Share Price
SharePrice
2.70
CY2016Q4 us-gaap Fair Value Assumptions Exercise Price
FairValueAssumptionsExercisePrice
3.90
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2016 us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.0123
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.900
CY2016Q4 bioc Warrants Issued Grant Date Fair Value
WarrantsIssuedGrantDateFairValue
5200000
CY2015Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2518158
CY2016Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2728468
CY2015Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
143726
CY2016Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
143726
CY2015Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
577898
CY2016Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
620582
CY2015Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
514614
CY2016Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
517968
CY2015Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
914179
CY2016Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
1559690
CY2015Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
70815
CY2016Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
169896
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4739390
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5740330
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3793210
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3933999
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
28981
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
20776
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
128753
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
168727
CY2015Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
307845
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
364953
CY2015Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
376100
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
422868
CY2015Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
76574
CY2016Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
77844
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
31170
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
67085
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17476
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
37783
CY2015 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
1076000
CY2016 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
1076000
CY2015 us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
77000
CY2016 us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
77000
CY2015Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
523000
CY2016Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
525000
CY2016 bioc Equipment Financings Aggregate Weighted Average Interest Rate
EquipmentFinancingsAggregateWeightedAverageInterestRate
0.1318
CY2016 bioc Equipment Financings Maturity Date Range Start
EquipmentFinancingsMaturityDateRangeStart
2017-07
CY2016 bioc Equipment Financings Maturity Date Range End
EquipmentFinancingsMaturityDateRangeEnd
2023-05
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
274367
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
242040
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
205067
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
203107
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
203107
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
381354
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
1509042
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
467725
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
1041317
CY2016Q4 bioc Capital Leases Maintenance Obligation Payments Due Current
CapitalLeasesMaintenanceObligationPaymentsDueCurrent
27495
CY2016Q4 bioc Capital Leases Maintenance Obligation Payments Due In Two Years
CapitalLeasesMaintenanceObligationPaymentsDueInTwoYears
27490
CY2016Q4 bioc Capital Leases Maintenance Obligation Payments Due In Three Years
CapitalLeasesMaintenanceObligationPaymentsDueInThreeYears
26733
CY2016Q4 bioc Capital Leases Maintenance Obligation Payments Due In Four Years
CapitalLeasesMaintenanceObligationPaymentsDueInFourYears
26664
CY2016Q4 bioc Capital Leases Maintenance Obligation Payments Due In Five Years
CapitalLeasesMaintenanceObligationPaymentsDueInFiveYears
26664
CY2016Q4 bioc Capital Leases Maintenance Obligation Payments Due Thereafter
CapitalLeasesMaintenanceObligationPaymentsDueThereafter
37774
CY2016Q4 bioc Capital Leases Maintenance Obligation Payments Due
CapitalLeasesMaintenanceObligationPaymentsDue
172820
CY2016Q4 bioc Capital Leases Maintenance Obligation Payments Net
CapitalLeasesMaintenanceObligationPaymentsNet
172820
CY2016Q4 bioc Equipment Financings Minimum Payments Present Value Due Within One Year
EquipmentFinancingsMinimumPaymentsPresentValueDueWithinOneYear
262674
CY2016 bioc Share Based Compensation Arrangement By Share Based Payment Award Number Of Equity Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEquityIncentivePlans
2
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
302015
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
441288
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
29644
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
713659
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
290399
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
107396
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
896662
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
801529
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.88
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.01
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.83
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.03
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.51
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.99
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.80
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.26
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
455237
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
CY2016Q4 bioc Common Stock Warrants Exercisable Intrinsic Value
CommonStockWarrantsExercisableIntrinsicValue
0
CY2016Q4 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
0
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1524170
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12695427
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1608
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2053
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1608
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2053
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5762293
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6255072
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-334494
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-260835
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
34852
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
67151
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
334609
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
157250
CY2015 bioc Income Tax Reconciliation Nondeductible Expense Interest
IncomeTaxReconciliationNondeductibleExpenseInterest
-316
CY2016 bioc Income Tax Reconciliation Nondeductible Expense Interest
IncomeTaxReconciliationNondeductibleExpenseInterest
21548
CY2015 bioc Income Tax Reconciliation Expiration Of Net Operating Losses
IncomeTaxReconciliationExpirationOfNetOperatingLosses
796699
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
164967
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
170950
CY2015 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
746238
CY2016 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
44421
CY2015 bioc Income Tax Reconciliation Section Three Eight Two Limitation
IncomeTaxReconciliationSectionThreeEightTwoLimitation
48484354
CY2016 bioc Income Tax Reconciliation Section Three Eight Two Limitation
IncomeTaxReconciliationSectionThreeEightTwoLimitation
9256295
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-1041
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
96406
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-44132033
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2954161
CY2015 bioc Percent Of Uncertain Income Tax Positions Recognized
PercentOfUncertainIncomeTaxPositionsRecognized
0.50
CY2016 bioc Percent Of Uncertain Income Tax Positions Recognized
PercentOfUncertainIncomeTaxPositionsRecognized
0.50
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6204024
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2218618
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2235914
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2244047
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1234413
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2273838
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
181134
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
164821
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9855485
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6901324
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9855485
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6901324
CY2016Q4 bioc Percentage Of Change In Ownership
PercentageOfChangeInOwnership
0.50
CY2016 bioc Period Of Change In Ownership
PeriodOfChangeInOwnership
P3Y
CY2016Q4 bioc Number Of Consultants
NumberOfConsultants
1
CY2016 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-07-31
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1272000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1272000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1348257
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1388705
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1430366
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
855136
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5022464
CY2016Q1 bioc Unconditional Purchase Commitment Quarterly Payment Amount
UnconditionalPurchaseCommitmentQuarterlyPaymentAmount
62500
CY2015Q1 us-gaap Cash
Cash
19294706
CY2015Q2 us-gaap Cash
Cash
16523975
CY2015Q3 us-gaap Cash
Cash
12541919
CY2015Q1 us-gaap Assets
Assets
20899513
CY2015Q2 us-gaap Assets
Assets
18317659
CY2015Q3 us-gaap Assets
Assets
14196386
CY2015Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5083216
CY2015Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4234552
CY2015Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3877362
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3553395
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
13582795
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
11049961
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
6928277
CY2015Q1 us-gaap Revenues
Revenues
150002
CY2015Q2 us-gaap Revenues
Revenues
76768
CY2015Q3 us-gaap Revenues
Revenues
164856
CY2015Q4 us-gaap Revenues
Revenues
218283
CY2015Q1 us-gaap Cost Of Revenue
CostOfRevenue
1147682
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
1013075
CY2015Q3 us-gaap Cost Of Revenue
CostOfRevenue
1159710
CY2015Q4 us-gaap Cost Of Revenue
CostOfRevenue
1275691
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
651420
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
744242
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
677729
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
784379
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1292049
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1359226
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1630608
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1404515
CY2015Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
709456
CY2015Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
851109
CY2015Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1055653
CY2015Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1264168
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3650605
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3890884
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4358844
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4510470
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-3800728
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-4035105
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-4496193
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-4617500
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3457556
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6005145
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6242604
CY2015Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6307316
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3457556
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6005145
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6242604
CY2015Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6307316
CY2015Q1 bioc Reclassification Of Revenue Generation Cost From Research And Development To Cost Of Revenue
ReclassificationOfRevenueGenerationCostFromResearchAndDevelopmentToCostOfRevenue
290709
CY2015Q2 bioc Reclassification Of Revenue Generation Cost From Research And Development To Cost Of Revenue
ReclassificationOfRevenueGenerationCostFromResearchAndDevelopmentToCostOfRevenue
27856
CY2016Q1 us-gaap Cash
Cash
4572750
CY2016Q2 us-gaap Cash
Cash
3751570
CY2016Q3 us-gaap Cash
Cash
678855
CY2016Q1 us-gaap Assets
Assets
6780830
CY2016Q2 us-gaap Assets
Assets
6303153
CY2016Q3 us-gaap Assets
Assets
3282549
CY2016Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3132372
CY2016Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3134593
CY2016Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2793258
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2526113
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
-489231
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
-419402
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
-4556158
CY2016Q1 us-gaap Revenues
Revenues
221369
CY2016Q2 us-gaap Revenues
Revenues
662860
CY2016Q3 us-gaap Revenues
Revenues
1047280
CY2016Q4 us-gaap Revenues
Revenues
1291587
CY2016Q1 us-gaap Cost Of Revenue
CostOfRevenue
1474790
CY2016Q2 us-gaap Cost Of Revenue
CostOfRevenue
1669571
CY2016Q3 us-gaap Cost Of Revenue
CostOfRevenue
1876288
CY2016Q4 us-gaap Cost Of Revenue
CostOfRevenue
1899462
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
728076
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
716279
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
600613
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
668399
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1487224
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1517664
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1918543
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1636994
CY2016Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1304899
CY2016Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1291709
CY2016Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1278455
CY2016Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1179167
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4773620
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4532363
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4626619
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4092435
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-4875198
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-4594174
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-4743076
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-4186874
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6566992
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7702286
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8370691
CY2016Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15620049
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6566992
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7702286
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8370691
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15620049

Files In Submission

Name View Source Status
0001564590-17-005382-index-headers.html Edgar Link pending
0001564590-17-005382-index.html Edgar Link pending
0001564590-17-005382.txt Edgar Link pending
0001564590-17-005382-xbrl.zip Edgar Link pending
bioc-10k_20161231.htm Edgar Link pending
bioc-20161231.xml Edgar Link completed
bioc-20161231.xsd Edgar Link pending
bioc-20161231_cal.xml Edgar Link unprocessable
bioc-20161231_def.xml Edgar Link unprocessable
bioc-20161231_lab.xml Edgar Link unprocessable
bioc-20161231_pre.xml Edgar Link unprocessable
bioc-ex311_8.htm Edgar Link pending
bioc-ex312_9.htm Edgar Link pending
bioc-ex321_6.htm Edgar Link pending
bioc-ex322_7.htm Edgar Link pending
bioc-ex43_269.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
govr4rnaf4bv000001.jpg Edgar Link pending
govr4rnaf4bv000002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending